This federal contract IDV award is for the provision of non-positron emission tomography (non-PET) radiopharmaceuticals to the Department of Veterans Affairs (VA) Veterans Integrated Service Network 21 (VISN 21). The prime contractor, RLS (USA) Inc., is a foreign-owned, for-profit radiopharmacy company that specializes in supplying radiopharmaceuticals and related services to federal government healthcare agencies, particularly the VA and Defense Health Agency (DHA).
The single-award indefinite delivery contract has a ceiling value of $2,182,424.43 and a period of performance from April 1, 2025 to March 31, 2030. Under this IDV, RLS (USA) Inc. will deliver a range of radiopharmaceutical products, including gallium-67, fluorodeoxyglucose F-18, thallium-201, technetium-99m, and Gallium-68 Dotatate, to support nuclear medicine diagnostic services at VA medical centers. The first task order, valued at $425,725.07, will cover the delivery of these non-PET radiopharmaceuticals to the VA Palo Alto Health Care System from April 1, 2025 to March 31, 2026. This procurement is an open market solicitation and not set aside for any specific business category.
Generated 4/2/25, 10:09 AM